As a preclinical stage life sciences start-up, Tellus is structured around demonstrating the safety and efficacy of new therapeutic interventions in critically ill newborns. Developing novel small molecules derived from human maternal breast milk, Tellus Theapeutics is translating break-through science licensed from Duke University that identifies compounds in breast milk that induce the regeneration of myelin-producing oligodendrocytes and that repaired WMI - white matter injury - in animal models of perinatal brain injury. Tellus' objective is provide a treatment for every baby born at risk for brain injury and to improve neurodevelopmental outcomes for affected children.
